LENZ Therapeutics, Inc.
LENZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13 | $5 | $0 | $0 |
| % Growth | 150% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $12 | $5 | $0 | $0 |
| % Margin | 99% | 100% | – | – |
| R&D Expenses | $4 | $9 | $6 | $6 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $27 | $13 | $11 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31 | $22 | $17 | $15 |
| Operating Income | -$19 | -$17 | -$17 | -$15 |
| % Margin | -151.1% | -337.1% | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $3 |
| Pre-Tax Income | -$17 | -$14 | -$15 | -$13 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$17 | -$15 | -$15 | -$13 |
| % Margin | -133.6% | -298.2% | – | – |
| EPS | -0.59 | -0.53 | -0.53 | -0.46 |
| % Growth | -11.3% | 0% | -15.2% | – |
| EPS Diluted | -0.59 | -0.53 | -0.53 | -0.46 |
| Weighted Avg Shares Out | 29 | 28 | 28 | 27 |
| Weighted Avg Shares Out Dil | 29 | 28 | 28 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$17 | -$17 | -$15 |
| % Margin | -132.6% | -336.8% | – | – |